Bevacizumab in first-line therapy for metastatic colorectal cancer in combination with FOLFOX or XELOX
2014
Abstract
Bevacizumab improves treatment outcomes compared with chemotherapy alone in patients with metastatic colorectal cancer (mCRC) regardless of KRAS mutation. In patients without KRAS mutation it is equivalent to monoclonal antibodies against the epidermal growth factor receptor.
The aim of our retrospective study based on data from the registry CORECT was to evaluate possible differences in treatment outcomes of patients treated with bevacizumab in combination with chemotherapy XELOX or FOLFOX as first-line. The results showed that XELOX and FOLFOX in combination with bevacizumab as first-line treatment of mCRC are equivalent.